Clariane (ENXTPA:CLARI) drew fresh attention after reporting half year 2026 results, highlighting higher operating EBITDA, lower net debt following a €1.063b bond issue, and reaffirmed medium term growth and margin objectives.
See our latest analysis for Clariane.
Clariane’s recent bond issue and half year 2026 earnings update arrived after a mixed period, with the share price up 3.05% year to date but the 1 year total shareholder return down 7.15%. This points to modest recent momentum while longer term returns remain weak, with the 5 year total shareholder return down 77.59%. This helps explain why investors are watching balance sheet repair and profitability trends so closely.
If you are weighing Clariane’s turnaround efforts against other ideas in your portfolio, this could be a useful moment to broaden your search and look at 104 top founder-led companies
After Clariane’s earnings bounce and balance sheet repair, the share price has only inched higher while long term returns remain weak. Is most of the recovery already reflected, or does the current valuation still leave meaningful upside?
Most Popular Narrative: 13.1% Undervalued
The most followed narrative puts Clariane’s fair value at €4.66, compared with the last close at €4.05, which frames the current valuation gap squarely around future earnings power and margins.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.7x on those 2029 earnings, down from 903.4x today. This future PE is greater than the current PE for the GB Healthcare industry at 17.7x.
Want to see why this narrative leans on stronger earnings and profit margins while revenue expectations stay more restrained? The full framework rests on calibrated growth assumptions, a richer earnings multiple, and a specific discount rate that together anchor that €4.66 fair value.
Result: Fair Value of €4.66 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Clariane still faces risks around French pricing pressure and higher refinancing costs, which could restrict margins and limit the extent to which the current narrative plays out.
Find out about the key risks to this Clariane narrative.
Another View on Clariane’s Valuation
The first narrative argues that Clariane looks undervalued at €4.05 compared with a €4.66 fair value. Yet on simple earnings multiples, the picture is very different. Clariane trades on a P/E of 114.9x, which appears high compared with a fair ratio of 28.6x.
That multiple is also well above the European Healthcare industry at 19.9x and a peer average of 15.6x. For investors, this raises a practical question: Is the low multiple story in the narrative more convincing than what today’s elevated P/E might indicate about valuation risk?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals around Clariane’s valuation, it makes sense to look at the underlying numbers yourself and decide how the risk reward trade off stacks up. To help frame both sides of that debate, take a closer look at the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Clariane?
If Clariane has sharpened your focus on valuation and risk, do not stop there. Fresh ideas from other corners of the market could reshape your watchlist.
- Spot potential value opportunities by scanning 245 high quality undervalued stocks that combine quality fundamentals with more modest pricing.
- Prioritise resilience by reviewing 303 resilient stocks with low risk scores that score well on stability and lower risk profiles.
- Hunt for less crowded opportunities by screening screener containing 548 high quality undiscovered gems that many investors may be overlooking.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com